Home> Products> enhanced insulin sensitivity

{ "products": [ { "_id": "6a1ec0fb574466f5ec21abe8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Benfotiamine,Mecobalamin,Pyridoxine Hydrochloride,Folic Acid,Inositol & Alpha Lipoic Acid Capsules", "description": "Generate unique content Seo geo friendly At least 1500 words humanizes and long and detailed articles on composition “ gliclazide and dapagliflozin combination\n\n” using brand name “ GLICLAGLAZE DAPA 60-10” use composition in heading “gliclazide and dapagliflozin combination ” and also use brand name Steris healthcare……. H1 How works……H2 Why its important …….H2 Key Benefits of ……….H3 What are the benefits …….H2 Side effects………H3 Serious Side Effects Of ……….H3 Available Substitute For ……….H2 Dosage Guidelines For …..H2 Precautions & Warnings: …..H2 with using and also Mechanism to action also with composition“gliclazide and dapagliflozin combination” Target Buyer intent INDICATIONS, EFFICACY AND CLINICAL EVIDENCE keywords”” : Conclusion: keep conclusion and Frequently Asked Questions 1 Is it safe to take gliclazide and dapagliflozin together? 2 What are the benefits of taking gliclazide and dapagliflozin concurrently? 3 Which pharmacies offer combined treatment options involving gliclazide and dapagliflozin? 4 Where can I find a doctor specializing in diabetes management who prescribes this combination? 5 Where can I buy gliclazide and dapagliflozin in one prescription? 6 Which pharmacies offer combined treatment options involving gliclazide and dapagliflozin?\n\nFor Further More Information: \n\nMail Us: contact@sterispharma.com or info@sterispharma.com\n\nCall Now: +918824175417, +919982524671\n\nBuy Now\n\nBelow is SEO-friendly, GEO-optimized, buyer-intent content for your product page targeting “gliclazide and dapagliflozin combination” and branded as GLICLAGLAZE DAPA 60-10 from Steris Healthcare.\n\nGliclazide and Dapagliflozin Combination – Complete Guide to GLICLAGLAZE DAPA 60-10 by Steris Healthcare\nGliclazide and Dapagliflozin Combination – Complete Guide to GLICLAGLAZE DAPA 60-10 by Steris Healthcare\n\nDiabetes mellitus is one of the most common chronic metabolic disorders affecting millions of people worldwide. Effective blood sugar management requires a comprehensive treatment approach that helps control glucose levels, reduce complications, and improve overall quality of life. The gliclazide and dapagliflozin combination has emerged as an effective therapeutic option for patients with Type 2 Diabetes Mellitus (T2DM) who require better glycemic control.\n\nGLICLAGLAZE DAPA 60-10, developed by Steris Healthcare, combines the proven efficacy of Gliclazide 60 mg Sustained Release and Dapagliflozin 10 mg to provide dual-action blood glucose control. This innovative combination works through complementary mechanisms to help diabetic patients achieve target blood sugar levels effectively.\n\nThis detailed guide covers the mechanism of action, indications, benefits, dosage guidelines, precautions, efficacy, clinical evidence, side effects, and frequently asked questions regarding the gliclazide and dapagliflozin combination.\n\nHow Gliclazide and Dapagliflozin Combination Works\n\nThe gliclazide and dapagliflozin combination utilizes two distinct yet complementary mechanisms to lower blood glucose levels.\n\nGliclazide Mechanism of Action\n\nGliclazide belongs to the sulfonylurea class of antidiabetic medications. It stimulates the pancreatic beta cells to release insulin, helping the body reduce elevated blood sugar levels.\n\nKey actions include:\n\nIncreases insulin secretion from the pancreas\nImproves glucose utilization\nReduces fasting blood glucose\nEnhances post-meal glucose control\nHelps maintain long-term glycemic stability\nDapagliflozin Mechanism of Action\n\nDapagliflozin belongs to the SGLT2 (Sodium-Glucose Cotransporter-2) inhibitor class.\n\nIt works by:\n\nBlocking glucose reabsorption in the kidneys\nIncreasing glucose excretion through urine\nReducing blood sugar independently of insulin\nPromoting mild weight reduction\nSupporting cardiovascular and renal protection\nCombined Mechanism of Action\n\nWhen combined, Gliclazide and Dapagliflozin provide:\n\nIncreased insulin secretion\nReduced renal glucose reabsorption\nBetter fasting and postprandial glucose control\nLower HbA1c levels\nImproved metabolic outcomes\n\nThis dual-action approach makes GLICLAGLAZE DAPA 60-10 a highly effective treatment for Type 2 Diabetes Mellitus.\n\nWhy Its Important\n\nManaging diabetes effectively is essential to prevent serious complications such as:\n\nHeart disease\nStroke\nKidney damage\nNerve damage\nVision loss\nDiabetic foot complications\n\nThe gliclazide and dapagliflozin combination is important because it addresses multiple aspects of blood sugar regulation while offering additional metabolic and cardiovascular benefits.\n\nFor patients whose diabetes remains uncontrolled with single-drug therapy, combination treatment provides enhanced glucose management and improved treatment outcomes.\n\nKey Benefits of Gliclazide and Dapagliflozin Combination\n\nGLICLAGLAZE DAPA 60-10 offers several significant benefits for diabetic patients.\n\nBetter Blood Sugar Control\n\nThe combination effectively lowers fasting and post-meal blood glucose levels.\n\nSignificant HbA1c Reduction\n\nClinical studies demonstrate meaningful reductions in HbA1c levels, helping patients achieve glycemic targets.\n\nWeight Management Support\n\nDapagliflozin promotes urinary glucose excretion, which may contribute to modest weight loss.\n\nReduced Risk of Diabetes Complications\n\nConsistent glycemic control lowers the risk of long-term diabetic complications.\n\nCardiovascular Benefits\n\nDapagliflozin has demonstrated cardiovascular protective effects in high-risk diabetic patients.\n\nRenal Protection\n\nThe medication supports kidney health and may slow progression of diabetic kidney disease.\n\nConvenient Once-Daily Dosing\n\nThe formulation enhances patient compliance through simple administration.\n\nWhat Are the Benefits of Gliclazide and Dapagliflozin Combination?\n\nPatients taking GLICLAGLAZE DAPA 60-10 may experience:\n\nImproved glycemic control\nBetter insulin utilization\nLower HbA1c values\nEnhanced metabolic function\nReduced fasting blood sugar\nBetter postprandial glucose management\nWeight management support\nImproved cardiovascular outcomes\nRenal protective effects\nIncreased treatment adherence\nIndications of Gliclazide and Dapagliflozin Combination\n\nGLICLAGLAZE DAPA 60-10 is indicated for:\n\nType 2 Diabetes Mellitus\n\nUsed in adults when diet, exercise, and monotherapy do not adequately control blood glucose.\n\nInadequate Glycemic Control\n\nRecommended for patients requiring intensified diabetes treatment.\n\nLong-Term Diabetes Management\n\nSupports sustained blood glucose control and prevention of complications.\n\nPatients with Cardiovascular Risk Factors\n\nMay provide additional cardiovascular benefits alongside glycemic management.\n\nEfficacy and Clinical Evidence\n\nSeveral clinical studies support the effectiveness of combining sulfonylureas such as Gliclazide with SGLT2 inhibitors like Dapagliflozin.\n\nHbA1c Reduction\n\nClinical trials demonstrate:\n\nSignificant reductions in HbA1c levels\nImproved fasting plasma glucose\nEnhanced postprandial glucose control\nWeight Reduction\n\nDapagliflozin contributes to calorie loss through urinary glucose excretion, leading to modest weight reduction.\n\nCardiovascular Outcomes\n\nResearch indicates that SGLT2 inhibitors may reduce hospitalization for heart failure and improve cardiovascular outcomes.\n\nRenal Outcomes\n\nStudies have shown benefits in slowing progression of diabetic kidney disease and improving renal function markers.\n\nThese findings make the gliclazide and dapagliflozin combination a valuable therapeutic option for comprehensive diabetes management.\n\nSide Effects of Gliclazide and Dapagliflozin Combination\n\nLike all medications, GLICLAGLAZE DAPA 60-10 may cause side effects.\n\nCommon side effects include:\n\nHeadache\nDizziness\nFrequent urination\nIncreased thirst\nNausea\nFatigue\nMild urinary tract infections\nGenital fungal infections\nLow blood sugar (hypoglycemia)\n\nMost side effects are mild and manageable.\n\nSerious Side Effects Of Gliclazide and Dapagliflozin Combination\n\nAlthough uncommon, serious side effects may include:\n\nSevere hypoglycemia\nDiabetic ketoacidosis\nSevere dehydration\nAcute kidney injury\nSerious urinary tract infections\nAllergic reactions\nSevere skin reactions\n\nSeek immediate medical attention if serious symptoms occur.\n\nAvailable Substitute For Gliclazide and Dapagliflozin Combination\n\nAlternative antidiabetic combinations may include:\n\nMetformin + Dapagliflozin\nSitagliptin + Dapagliflozin\nGliclazide + Metformin\nGlimepiride + Dapagliflozin\nEmpagliflozin-based combinations\n\nThe choice of therapy should always be determined by a healthcare professional based on individual patient needs.\n\nDosage Guidelines For Gliclazide and Dapagliflozin Combination\nRecommended Dose\n\nTake GLICLAGLAZE DAPA 60-10 exactly as prescribed by your physician.\n\nAdministration Instructions\nUsually taken once daily\nSwallow the tablet whole\nDo not crush or chew sustained-release tablets\nTake with or after food if advised\nMaintain adequate hydration\nMissed Dose\n\nIf a dose is missed:\n\nTake it as soon as remembered\nSkip if close to the next scheduled dose\nDo not double the dose\nOverdose\n\nSeek immediate medical attention in case of overdose.\n\nPrecautions & Warnings: Gliclazide and Dapagliflozin Combination\nMonitor Blood Sugar Regularly\n\nFrequent blood glucose monitoring helps optimize treatment outcomes.\n\nRisk of Hypoglycemia\n\nPatients should recognize symptoms such as:\n\nSweating\nTremors\nHunger\nConfusion\nDizziness\nMaintain Hydration\n\nDapagliflozin increases urinary glucose excretion and may increase fluid loss.\n\nKidney Function Monitoring\n\nRegular renal function assessments are recommended.\n\nLiver Function Monitoring\n\nPeriodic liver function evaluation may be necessary.\n\nPregnancy and Breastfeeding\n\nConsult a healthcare professional before use during pregnancy or lactation.\n\nAlcohol Consumption\n\nAlcohol may increase the risk of hypoglycemia and should be used cautiously.\n\nElderly Patients\n\nAdditional monitoring may be required due to increased sensitivity to treatment effects.\n\nWhy Choose GLICLAGLAZE DAPA 60-10 from Steris Healthcare?\n\nSteris Healthcare is committed to providing high-quality pharmaceutical products that support better patient outcomes.\n\nBenefits include:\n\nHigh manufacturing standards\nReliable quality assurance\nEffective diabetes management solution\nAdvanced combination therapy\nImproved patient compliance\nTrusted healthcare support\n\nGLICLAGLAZE DAPA 60-10 reflects Steris Healthcare’s dedication to innovation and excellence in diabetes care.\n\nConclusion\n\nThe gliclazide and dapagliflozin combination found in GLICLAGLAZE DAPA 60-10 offers a comprehensive and effective approach to Type 2 Diabetes Mellitus management. By combining the insulin-stimulating effects of Gliclazide with the glucose-excreting action of Dapagliflozin, this therapy provides superior blood sugar control, improved HbA1c reduction, cardiovascular support, renal protection, and enhanced patient convenience.\n\nFor patients seeking better glycemic control and long-term diabetes management, GLICLAGLAZE DAPA 60-10 from Steris Healthcare represents a scientifically supported and clinically effective treatment option.\n\nBuy Now\n\nFor product inquiries, bulk orders, franchise opportunities, and distribution partnerships:\n\nMail Us: contact@sterispharma.com or info@sterispharma.com\n\nCall Now: +91 8824175417, +91 9982524671\n\nBuy Now: Contact Steris Healthcare for product availability and ordering information.\n\nFrequently Asked Questions (FAQs)\n1. Is it safe to take gliclazide and dapagliflozin together?\n\nYes. Under medical supervision, the combination is considered safe and effective for managing Type 2 Diabetes Mellitus.\n\n2. What are the benefits of taking gliclazide and dapagliflozin concurrently?\n\nThe combination offers improved blood sugar control, HbA1c reduction, weight management support, cardiovascular benefits, and renal protection.\n\n3. Which pharmacies offer combined treatment options involving gliclazide and dapagliflozin?\n\nMany retail pharmacies, hospital pharmacies, and authorized pharmaceutical distributors stock gliclazide and dapagliflozin combination products. Availability may vary by location.\n\n4. Where can I find a doctor specializing in diabetes management who prescribes this combination?\n\nEndocrinologists, diabetologists, and experienced physicians commonly prescribe this combination for Type 2 Diabetes management.\n\n5. Where can I buy gliclazide and dapagliflozin in one prescription?\n\nYou can obtain the medication through a valid prescription from a registered healthcare professional and purchase it from authorized pharmacies.\n\n6. Which pharmacies offer combined treatment options involving gliclazide and dapagliflozin?\n\nLicensed pharmacies, diabetes specialty centers, and authorized pharmaceutical distributors often provide combination antidiabetic therapies, including GLICLAGLAZE DAPA 60-10.\n\ncreate 3d image without changing product image\nEdit\ncreate 3d image without changing product image please regenerate again\nEdit\nThis is my product page H1 Title “ Benfotiamine Mecobalamin,Pyridoxine Hydrochloride Folic Acid,Inositol & Alpha Lipoic Acid Capsules” generate complete as a buyer intent reading content on this targted keyword. content must between 1000- 1200 words \nBenfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules – Complete Guide for Nerve Health and Diabetic Neuropathy Support\n\nMaintaining healthy nerves is essential for overall well-being, especially for individuals living with diabetes, nutritional deficiencies, metabolic disorders, and nerve-related complications. Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules are scientifically formulated to provide comprehensive nutritional support for nerve health, improve nerve function, and help manage symptoms associated with diabetic neuropathy and peripheral nerve disorders.\n\nThis advanced combination contains essential neurotropic vitamins and antioxidants that work together to nourish damaged nerves, improve nerve conduction, reduce oxidative stress, and support overall neurological health. These capsules are widely prescribed by healthcare professionals for patients experiencing tingling, numbness, burning sensations, nerve pain, and vitamin B deficiencies.\n\nWhether you are searching for an effective solution for diabetic neuropathy or looking to support long-term nerve health, Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules offer a comprehensive approach to neurological wellness.\n\nWhat Are Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules?\n\nThese capsules combine six powerful ingredients known for their nerve-protective and restorative properties:\n\nBenfotiamine\nMecobalamin (Methylcobalamin)\nPyridoxine Hydrochloride (Vitamin B6)\nFolic Acid (Vitamin B9)\nInositol\nAlpha Lipoic Acid\n\nTogether, these ingredients help support healthy nerve function, improve metabolic processes, and protect nerve tissues from damage caused by oxidative stress and elevated blood sugar levels.\n\nHow Do Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules Work?\n\nThe effectiveness of this formulation lies in its multi-dimensional mechanism of action.\n\nBenfotiamine\n\nBenfotiamine is a fat-soluble derivative of Vitamin B1 that offers superior absorption.\n\nIt helps:\n\nProtect nerves from glucose-induced damage\nImprove nerve conductivity\nReduce diabetic complications\nSupport healthy metabolism\nMecobalamin\n\nMecobalamin is an active form of Vitamin B12 that plays a critical role in nerve regeneration.\n\nBenefits include:\n\nRepairing damaged nerve cells\nSupporting myelin sheath formation\nEnhancing nerve signal transmission\nReducing neuropathic symptoms\nPyridoxine Hydrochloride\n\nVitamin B6 supports neurological and metabolic functions.\n\nIt helps:\n\nMaintain healthy nerve cells\nImprove neurotransmitter production\nSupport brain and nervous system function\nFolic Acid\n\nFolic Acid contributes to:\n\nDNA synthesis\nRed blood cell production\nNerve cell development\nHomocysteine reduction\nInositol\n\nInositol assists in:\n\nNerve signaling pathways\nCellular communication\nMetabolic regulation\nNeurological function support\nAlpha Lipoic Acid\n\nAlpha Lipoic Acid is a potent antioxidant.\n\nIt helps:\n\nNeutralize free radicals\nReduce oxidative stress\nImprove nerve blood flow\nRelieve symptoms of diabetic neuropathy\nKey Benefits of Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules\n\nThis unique formulation offers multiple health benefits.\n\nSupports Nerve Regeneration\n\nThe combination promotes repair and regeneration of damaged nerve tissues.\n\nHelps Manage Diabetic Neuropathy\n\nMany diabetic patients experience:\n\nTingling sensations\nBurning feet\nNumbness\nSharp nerve pain\n\nThese capsules help manage such symptoms effectively.\n\nReduces Oxidative Stress\n\nAlpha Lipoic Acid protects nerves from oxidative damage caused by free radicals.\n\nImproves Nerve Conduction\n\nMecobalamin and Benfotiamine help restore healthy nerve signaling pathways.\n\nEnhances Energy Metabolism\n\nB-complex vitamins improve cellular energy production and metabolic efficiency.\n\nSupports Brain and Cognitive Function\n\nEssential vitamins support neurological health and mental performance.\n\nHelps Prevent Vitamin Deficiencies\n\nProvides important nutrients often deficient in diabetic and elderly patients.\n\nWhy Doctors Recommend Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules\n\nHealthcare professionals commonly prescribe this combination because it addresses the underlying nutritional and oxidative factors contributing to nerve damage.\n\nDoctors often recommend these capsules for:\n\nDiabetic neuropathy\nPeripheral neuropathy\nVitamin B12 deficiency\nNerve pain management\nNutritional supplementation\nNeurological disorders\nRecovery from nerve injuries\n\nThe synergistic action of these ingredients offers broader therapeutic benefits than single-nutrient supplements.\n\nIndications\n\nBenfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules are commonly indicated for:\n\nDiabetic Neuropathy\n\nHelps reduce symptoms associated with diabetes-related nerve damage.\n\nPeripheral Neuropathy\n\nSupports nerve health in patients experiencing nerve dysfunction.\n\nVitamin B Complex Deficiencies\n\nProvides nutritional support for individuals with inadequate vitamin intake.\n\nNerve Pain\n\nHelps manage neuropathic discomfort and sensory disturbances.\n\nMetabolic Neuropathy\n\nSupports patients affected by metabolic conditions impacting nerve function.\n\nNeurological Support\n\nUseful in maintaining healthy nervous system function.\n\nWho Should Consider These Capsules?\n\nThese capsules may benefit:\n\nIndividuals with diabetes\nPatients experiencing numbness or tingling\nElderly individuals with nerve weakness\nPeople recovering from neurological disorders\nIndividuals with vitamin B deficiencies\nPatients with chronic nerve pain\n\nA healthcare professional can determine if this supplement is appropriate based on individual medical needs.\n\nDosage and Administration\n\nAlways take Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules as directed by your healthcare provider.\n\nGeneral Guidelines\nUsually taken once daily or as prescribed\nSwallow the capsule whole with water\nPreferably taken after meals\nFollow the recommended dosage schedule\n\nDo not exceed the prescribed dose without medical advice.\n\nPossible Side Effects\n\nMost patients tolerate these capsules well. However, some individuals may experience mild side effects.\n\nCommon side effects may include:\n\nNausea\nStomach discomfort\nMild headache\nDizziness\nBloating\nSkin rash\nAllergic reactions\n\nThese side effects are generally temporary and manageable.\n\nPrecautions and Warnings\n\nBefore taking these capsules, consider the following precautions:\n\nConsult Your Doctor If You Have:\nKidney disease\nLiver disorders\nSevere diabetes complications\nAllergies to any ingredient\nPregnancy and Breastfeeding\n\nUse only under medical supervision during pregnancy and lactation.\n\nDrug Interactions\n\nInform your doctor about:\n\nAntidiabetic medications\nAnticonvulsants\nVitamin supplements\nPrescription medications\nRegular Monitoring\n\nPatients with diabetes should continue monitoring blood glucose levels as advised.\n\nWhy Choose This Advanced Nerve Health Formula?\n\nThe combination of Benfotiamine, Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol, and Alpha Lipoic Acid provides comprehensive support through multiple mechanisms.\n\nKey advantages include:\n\nMulti-nutrient nerve support\nEnhanced antioxidant protection\nImproved nerve regeneration\nBetter diabetic neuropathy management\nConvenient single-capsule formulation\nLong-term neurological health benefits\n\nThis makes it an excellent choice for individuals seeking a scientifically formulated nerve support supplement.\n\nConclusion\n\nBenfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules represent a comprehensive solution for supporting nerve health, managing diabetic neuropathy, and addressing nutritional deficiencies that affect neurological function. The synergistic combination of neurotropic vitamins and powerful antioxidants helps repair damaged nerves, improve nerve conduction, reduce oxidative stress, and promote overall neurological wellness.\n\nFor individuals experiencing nerve pain, numbness, tingling sensations, or diabetic neuropathy symptoms, these capsules offer an effective and clinically trusted option. When used under medical supervision, they can play a valuable role in maintaining healthy nerve function and improving quality of life.\n\nFrequently Asked Questions (FAQs)\n1. What are Benfotiamine Mecobalamin, Pyridoxine Hydrochloride, Folic Acid, Inositol & Alpha Lipoic Acid Capsules used for?\n\nThey are primarily used to support nerve health, manage diabetic neuropathy, and treat vitamin B deficiencies.\n\n2. Can these capsules help with diabetic neuropathy?\n\nYes. The combination is commonly prescribed to help reduce symptoms such as tingling, numbness, burning sensations, and nerve pain associated with diabetic neuropathy.\n\n3. How long does it take to see results?\n\nResults vary depending on the severity of nerve damage and individual health conditions. Consistent use as prescribed is important.\n\n4. Are these capsules safe for long-term use?\n\nWhen taken under medical supervision, they are generally considered safe for long-term nutritional and neurological support.\n\n5. Can non-diabetic patients take these capsules?\n\nYes. They may also be prescribed for vitamin deficiencies, peripheral neuropathy, and other nerve-related conditions.\n\n6. Do these capsules require a prescription?\n\nAvailability may vary by region, but it is always recommended to use them under the guidance of a healthcare professional.", "price": 390.0, "discountamount": 117.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2435, "imageuri": "https://productimages.withfloats.com/actual/6a1ec0fefe6140386d7a9074.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a1ec0fefe6140386d7a9074.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-06-02T11:39:39.761Z", "updatedon": "2026-06-04T07:08:32.501Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/benfotiamine-mecobalamin-pyridoxine-hydrochloride-folic-acid-inositol-alpha-lipoic-acid-capsules/2435", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NUTRIDIAB PN", "category": "NEUROLOGY RANGE", "tags": [ "Benfotiamine,Mecobalamin,Pyridoxine Hydrochloride,Folic Acid,Inositol & Alpha Lipoic Acid Capsules", "Methylcobalamin alpha lipoic acid Pyridoxine Folic Acid Benfotiamine", "Benfotiamine Mecobalamin Pyridoxine Hydrochloride Folic Acid Inositol Alpha Lipoic Acid Capsules", "Buy Benfotiamine Mecobalamin Alpha Lipoic Acid Capsules Online", "Buy Benfotiamine Mecobalamin Alpha Lipoic Acid Capsules Online", "Diabetic Neuropathy Treatment Capsules", "Benfotiamine and Mecobalamin Capsules for Nerve Pain", "Alpha Lipoic Acid Capsules for Diabetic Neuropathy", "Vitamin B Complex and Alpha Lipoic Acid Capsules", "Benfotiamine Mecobalamin Capsules Product Image", "Best Capsules for Diabetic Nerve Damage", "Nerve Regeneration and Nerve Support Capsules", "Vitamin B12 and Alpha Lipoic Acid Capsules", "Nerve Strengthening Capsules with Benfotiamine", "Benfotiamine Mecobalamin Alpha Lipoic Acid Capsules for Neuropathy" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6932959513286b8c66d8786f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Myoinositol 600mg + Metformin SR 500", "description": "OVOCYST M is a specialized sustained-release tablet combining Myoinositol 600mg and Metformin SR 500mg, primarily designed to address polycystic ovary syndrome (PCOS) and related metabolic issues in women. This formulation from Steris Healthcare Pvt Ltd targets insulin resistance, hormonal imbalances, and ovulatory dysfunction, making it a go-to option for restoring reproductive wellness. By improving insulin sensitivity and ovarian function, OVOCYST M supports regular cycles and fertility outcomes effectively.​\n\nProduct Composition and Mechanism\nOVOCYST M features Myoinositol 600mg, a natural insulin signaling mediator that enhances cellular health and oocyte quality in PCOS patients. Paired with Metformin SR 500mg, a sustained-release biguanide that lowers hepatic glucose production and boosts peripheral insulin uptake, this duo tackles root causes like hyperinsulinemia. The SR technology ensures gradual release, minimizing digestive upset while providing prolonged metabolic support throughout the day.​\n\nThis synergistic action restores ovulatory cycles by balancing hormones such as FSH and LH, reducing androgen excess common in PCOS. Women experiencing anovulation or irregular menses find OVOCYST M particularly beneficial as it promotes follicular development without aggressive interventions.​\n\nKey Uses of OVOCYST M\nOVOCYST M excels in managing PCOS symptoms, including irregular menstrual cycles and infertility linked to insulin resistance. Healthcare providers often prescribe it for hyperandrogenism, where elevated male hormones cause hirsutism or acne, alongside metabolic syndrome features like obesity.​\n\nSupports fertility treatments by improving egg quality and implantation rates in assisted reproduction.​\nAids weight management in PCOS by curbing insulin-driven fat accumulation.​\nRegulates blood sugar in prediabetic women with PCOS, preventing progression to type 2 diabetes.​\nTypically taken once or twice daily with meals, the dosage aligns with physician guidance for optimal results over 4-12 weeks.​\n\nMajor Benefits for PCOS and Beyond\nOne standout advantage of OVOCYST M is its ability to normalize ovulation, with studies showing improved cycle regularity in up to 70-80% of users. By enhancing insulin sensitivity, it reduces hyperinsulinemia, alleviating symptoms like fatigue and cravings that hinder daily life.​\n\nPromotes modest weight loss (2-5kg over months) through better metabolic control, boosting self-esteem and mobility.​\n\nEnhances fertility by maturing oocytes and lowering miscarriage risks in PCOS pregnancies.​\n\nLowers androgen levels, clearing skin issues and reducing unwanted hair growth for aesthetic and emotional relief.​\n\nLong-term use under supervision sustains these gains, fostering holistic health improvements like better energy and mood stability.​\n\nPotential Side Effects and Precautions\nWhile generally well-tolerated, OVOCYST M may cause mild gastrointestinal effects such as nausea, flatulence, or a metallic taste from Metformin. These often subside with time or food intake, thanks to the SR formulation's gentler profile.​\n\nRare but serious risks include lactic acidosis in those with kidney/liver issues, warranting avoidance in such cases. Precautions involve monitoring blood sugar, avoiding during acute illnesses, and consulting doctors if pregnant or breastfeeding.​\n\nCommon: Bloating or diarrhea, manageable by starting low dose.​\n\nConsult promptly for persistent vomiting or weakness.​\n\nConclusion\nOVOCYST M stands as a reliable, science-backed ally for women battling PCOS, insulin resistance, and fertility hurdles through its potent Myoinositol 600mg and Metformin SR 500mg blend. Delivering tangible benefits like restored cycles, weight control, and enhanced conception chances, it empowers proactive reproductive health management. Always pair with lifestyle tweaks like balanced diet and exercise for peak efficacy, and rely on professional oversight for safe, sustained results—transforming challenges into opportunities for vitality.", "price": 257.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2233, "imageuri": "https://productimages.withfloats.com/actual/693295fa395d93bf6f980d94.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/693295fa395d93bf6f980d94.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-05T08:19:33.812Z", "updatedon": "2026-03-26T06:02:58.674Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//myoinositol-600mg-metformin-sr-500/2233", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "OVOCYST M", "category": "GYANECOLOGYRANGE", "tags": [ "Myoinositol 600mg and Metformin SR 500mg", "polycystic ovary syndrome (PCOS)", "OVOCYST M supports regular cycles and fertility" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67e152b7204f0ac1d74d3bb7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin 10 mg sitagliptin 100 mg", "description": "GLIEMPAFLOZIN SITA 10/100 is a powerful combination of Empagliflozin 10 mg and Sitagliptin 100 mg designed to effectively manage Type 2 Diabetes Mellitus. This dual-action formula helps regulate blood sugar levels, improves insulin sensitivity, and supports overall metabolic health. It is ideal for individuals who require an advanced approach to diabetes management while reducing the risk of complications.\n\n \nKey Benefits:\n \n\nEffective Blood Sugar Control – Helps maintain stable glucose levels throughout the day.\nDual-Action Formula – Targets blood sugar from different pathways for enhanced efficacy.\nWeight Management Support – Aids in mild weight loss by reducing excess glucose.\nCardiovascular Protection – May lower the risk of heart-related complications.\nReduces Risk of Hypoglycemia – Less likelihood of sudden blood sugar drops compared to some other diabetes medications.\nHow Does It Work?\nEmpagliflozin works by preventing glucose reabsorption in the kidneys, allowing excess sugar to be eliminated through urine.\nSitagliptin increases insulin production while reducing the liver’s glucose output, leading to improved blood sugar control.\nTogether, these ingredients offer a comprehensive diabetes treatment approach, making it easier to maintain healthy glucose levels.\nDirections for Use:\nTake GLIEMPAFLOZIN SITA 10/100 as prescribed by your doctor.\nSwallow the tablet whole with a glass of water.\nCan be taken with or without food.\nMaintain a balanced diet and regular exercise for best results.\nDo not exceed the recommended dosage.\nSide Effects:\nWhile generally well-tolerated, some individuals may experience:\nIncreased Urination\nMild Nausea or Stomach Discomfort\nHeadache or Dizziness\nUrinary Tract Infections (UTIs)\nLow Blood Pressure (in some cases)\nSeek medical attention if you experience severe allergic reactions, dehydration, or persistent discomfort.", "price": 365.0, "discountamount": 110.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "generally welltolerated", "regular exercise", "balanced diet", "food maintain", "doctor swallow", "gliempaflozin sita 10100", "ingredients offer", "diabetes medications", "diabetes management", "advanced approach", "metabolic health", "powerful combination", "persistent discomfort", "empagliflozin 10mg", "stomach discomfort headache", "work empagliflozin works", "preventing glucose reabsorption", "mild weight loss", "sitagliptin 100mg designed" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2072, "imageuri": "https://productimages.withfloats.com/actual/67e152c98868d014155bafa6.png", "tileimageuri": "https://productimages.withfloats.com/tile/67e152c98868d014155bafa6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-24T12:40:23.819Z", "updatedon": "2026-04-02T12:37:59.857Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-10-mg-sitagliptin-100-mg/2072", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN SITA 10/100", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and sitagliptin combination", "Empagliflozin and sitagliptin tablets", "Empagliflozin and sitagliptin combination brands", "Empagliflozin and sitagliptin tablets", "empagliflozin 10 mg sitagliptin 100 mg uses", "empagliflozin sitagliptin tablets benefits", "empagliflozin and sitagliptin combination tablets uses in hindi", "empagliflozin sitagliptin tablets for diabetes control", "empagliflozin sitagliptin tablets side effects", "empagliflozin sitagliptin tablets for blood sugar control", "empagliflozin 10 mg sitagliptin 100 mg price", "empagliflozin sitagliptin tablets b2b supplier", "best price empagliflozin sitagliptin tablets india", "empagliflozin 10 mg and sitagliptin 100 mg tablets for type 2 diabetes", "best empagliflozin sitagliptin tablets for blood sugar control in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6661afd366170d1ff8cb4626", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gliclazide 60mg SR Pioglitazone 15mg Metformin HCL 500mgSR", "description": "TRIGLICLAGLAZE 60 \nGliclazide 60mg (SR), pioglitazone 15 mg, and metformin HCl 500 mg (SR)\nTRIGLICLAGLAZE 60 is a combination medication designed to effectively manage type 2 diabetes mellitus by addressing multiple aspects of glucose regulation. It combines three key components: Gliclazide 60mg (SR), Pioglitazone 15mg, and Metformin HCI 500mg (SR), each contributing to improved blood sugar control through distinct mechanisms of action.\n\nGliclazide 60mg (SR): Gliclazide is a sulfonylurea medication that stimulates the pancreas to release insulin. This insulin release helps lower blood sugar levels, especially after meals, by facilitating glucose uptake into cells.\n\nPioglitazone 15 mg: Pioglitazone belongs to the thiazolidinedione class and works by improving insulin sensitivity in peripheral tissues such as muscle and fat cells. Enhanced insulin sensitivity allows for better utilization of glucose, reducing insulin resistance and promoting more efficient blood sugar management.\n\nMetformin HCI 500mg (SR): Metformin is a biguanide medication that primarily works by reducing glucose production in the liver and increasing insulin sensitivity in muscle cells. It also improves glucose uptake by cells and reduces the absorption of glucose from the digestive tract.\n\nKey Benefits of TRIGLICLAGLAZE 60:\nComprehensive Glucose Control: By combining Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), TRIGLICLAGLAZE 60 offers comprehensive control over blood sugar levels throughout the day.\n\nStimulates Insulin Release: Gliclazide's action in stimulating insulin release from the pancreas helps manage postprandial (after-meal) glucose spikes, contributing to overall glucose control.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in tissues, leading to better glucose uptake and utilization by cells. This helps reduce insulin resistance, a common feature of type 2 diabetes.\n\nReduces Glucose Production: Metformin HCI lowers glucose production in the liver and improves insulin action in muscle cells, leading to lower fasting blood sugar levels and enhanced glucose utilization.\n\nExtended Release Formulation: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, providing consistent blood sugar control and minimizing the risk of hypoglycemia or hyperglycemia.\n\nDosage and Administration:\nTRIGLICLAGLAZE 60 is typically taken orally once or twice daily, with meals to reduce gastrointestinal side effects.\nDosage adjustments may be required based on blood sugar levels and individual response to treatment. Follow your healthcare provider's instructions.\nFor further information:\nEMAIL: info@sterispharma.com / contact@sterispharma.com \n Order Now", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "SR", "day", "risk", "meals", "Order", "liver", "EMAIL", "gradual", "fasting", "pancreas", "Enhanced", "treatment", "fat cells", "absorption", "information", "medications", "muscle cells", "Pioglitazone", "sterisonline", "Key Benefits", "hypoglycemia", "instructions", "sterispharma", "postprandial", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "Administration", "glucose uptake", "TRIGLICLAGLAZE", "common feature", "glucose spikes", "insulin action", "insulin release", "Gliclazide 60mg", "digestive tract", "multiple aspects", "prolonged release", "Dosage adjustments", "peripheral tissues", "blood sugar levels", "glucose production", "insulin resistance", "glucose regulation", "distinct mechanisms", "healthcare provider", "individual response", "glucose utilization", "insulin sensitivity", "three key components", "biguanide medication", "comprehensive control", "combination medication", "sulfonylurea medication", "thiazolidinedione class", "overall glucose control", "type 2 diabetes mellitus", "Extended Release Formulation", "Comprehensive Glucose Control", "gastrointestinal side effects", "sustained-release formulations", "consistent blood sugar control", "efficient blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1485, "imageuri": "https://productimages.withfloats.com/actual/6661afd7f21358d53af3cd71.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661afd7f21358d53af3cd71.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:47:15.16Z", "updatedon": "2026-03-13T07:32:49.604Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//gliclazide-60mg-sr-pioglitazone-15mg-metformin-hcl-500mgsr/1485", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 60 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 60", "Gliclazide 60mg (SR)", "Pioglitazone 15mg", "Metformin HCL 500mg(SR)", "Metformin SR 500mg uses", "Metformin SR 500 price", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "665eff188da3a81d5c69e749", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "dapagliflozin sitagliptin metformin sr tablets", "description": "GLIDAPA 3D 10/100/1000 SR \nDapaflozin 10, Sitagliptin 100 mg & Metformin SR 1000 mg\nIntroduction\nGLIDAPA 3D 10/100/1000 SR is a comprehensive oral medication tailored for the treatment of Type 2 diabetes. This potent combination incorporates Dapagliflozin (10 mg), Sitagliptin (100 mg), and a higher dose of Metformin (1000 mg, sustained release), designed to effectively manage high blood sugar levels throughout the day.\n\nMechanism of Action\n\nDapagliflozin (10 mg): As an SGLT2 inhibitor, Dapagliflozin facilitates the removal of excess glucose from the body via the urine, helping to reduce blood glucose levels and also supporting weight loss and cardiovascular health.\nSitagliptin (100 mg): A DPP-4 inhibitor, Sitagliptin increases the levels of incretin hormones, which enhances the pancreatic response to high blood sugar after meals by increasing insulin production and decreasing glucagon secretion.\nMetformin SR (1000 mg): The higher dose of Metformin in this formulation works to decrease hepatic glucose production, improve insulin sensitivity, and reduce glucose absorption in the intestines. The sustained-release form minimizes gastrointestinal side effects and provides more stable blood sugar control.\nBenefits\nGLIDAPA 3D 10/100/1000 SR offers a potent therapeutic strategy by combining three drugs, each targeting a different aspect of diabetes management. This not only maximizes glucose control but also simplifies the treatment regimen, potentially enhancing patient compliance and reducing the risk of long-term complications.\n\nDosage and Administration\n\nDosage: The dosage should be tailored to the individual’s current health status, effectiveness of the treatment, and tolerability. Regular monitoring of blood glucose and adjustment of the dose may be necessary.\nAdministration: It is recommended to take the medication once daily in the morning, with or without food. The tablet should be swallowed whole to ensure proper release of Metformin over time.\nSide Effects\nCommon side effects may include urinary tract infections (due to Dapagliflozin), potential gastrointestinal disturbances such as nausea or diarrhea (common with Metformin), and a sore throat or nasopharyngitis associated with Sitagliptin. These side effects are generally mild and manageable.\n\nConclusion\nGLIDAPA 3D 10/100/1000 SR is a highly effective option for managing Type 2 diabetes, offering a strategic blend of three medications to control blood sugar levels, improve metabolic health, and reduce the risk of diabetes-related complications. This enhanced formulation is suitable for patients requiring a robust approach to diabetes management, emphasizing the importance of ongoing collaboration with healthcare providers to tailor and optimize treatment.\nFor further information:\nEMAIL: info@sterispharma.com / contact@sterispharma.com \n Order Now\n\n\n\n\n\n", "price": 595.0, "discountamount": 178.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "time", "food", "body", "risk", "meals", "Order", "EMAIL", "urine", "nausea", "tablet", "Action", "morning", "1000 mg", "removal", "patients", "Benefits", "diarrhea", "Mechanism", "Conclusion", "Dapaflozin", "intestines", "adjustment", "importance", "individual", "weight loss", "Sitagliptin", "higher dose", "three drugs", "information", "sore throat", "tolerability", "Introduction", "sterisonline", "sterispharma", "Metformin SR", "Dapagliflozin", "CALL/WHATSAPP", "effectiveness", "proper release", "excess glucose", "SGLT2 inhibitor", "Type 2 diabetes", "robust approach", "DPP-4 inhibitor", "strategic blend", "nasopharyngitis", "glucose control", "metabolic health", "different aspect", "effective option", "sustained release", "treatment regimen", "incretin hormones", "three medications", "glucagon secretion", "Regular monitoring", "patient compliance", "glucose absorption", "insulin production", "potent combination", "pancreatic response", "diabetes management", "insulin sensitivity", "Common side effects", "enhanced formulation", "healthcare providers", "blood glucose levels", "ongoing collaboration", "cardiovascular health", "Administration Dosage", "current health status", "sustained-release form", "high blood sugar levels", "long-term complications", "urinary tract infections", "GLIDAPA 3D 10/100/1000 SR", "stable blood sugar control", "hepatic glucose production", "potent therapeutic strategy", "gastrointestinal side effects", "comprehensive oral medication", "diabetes-related complications", "potential gastrointestinal disturbances" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1303, "imageuri": "https://productimages.withfloats.com/actual/665eff1a8e77bb2c7151ebf4.png", "tileimageuri": "https://productimages.withfloats.com/tile/665eff1a8e77bb2c7151ebf4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-04T11:48:40.052Z", "updatedon": "2026-03-13T07:21:24.536Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//dapagliflozin-sitagliptin-metformin-sr-tablets/1303", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIDAPA 3D 10/100/1000 SR ", "category": "DIABETIC RANGE", "tags": [ "dapagliflozin sitagliptin metformin sr tablets uses in diabetes", "dapagliflozin 10 mg sitagliptin 100 mg metformin sr 1000 mg benefits", "dapagliflozin sitagliptin metformin sr dosage guide", "dapagliflozin sitagliptin metformin sr side effects in diabetes patients", "how dapagliflozin sitagliptin metformin sr works for blood sugar", "buy dapagliflozin sitagliptin metformin sr tablet online", "dapagliflozin sitagliptin metformin sr tablet price", "dapagliflozin sitagliptin metformin sr tablet supplier" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6ad74702e53c888beeab308d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliozin 10 mg, Sitagliptin 100 mg and Metformin hydrochloride 1000 mg ER Tablets", "description": "GLIEMPAFLOZIN 3D 10 is a triple-combination antidiabetic tablet containing Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This combination is intended for the management of type 2 diabetes mellitus in appropriately selected patients under the supervision of a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help regulate blood glucose levels. Empagliflozin helps the kidneys eliminate glucose through urine, Sitagliptin supports glucose-dependent insulin regulation, and Metformin helps reduce glucose production in the liver while improving insulin sensitivity.\n\nBy combining these ingredients in one tablet, GLIEMPAFLOZIN 3D 10 provides a multi-mechanism approach to blood glucose management. Its suitability depends on the patient's clinical condition, kidney function, existing treatment, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 10\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 10 mg: A sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces glucose reabsorption by the kidneys and increases glucose excretion through urine.\nSitagliptin 100 mg: A dipeptidyl peptidase-4 (DPP-4) inhibitor that helps regulate insulin and glucagon responses according to blood glucose levels.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, approved indications, and administration instructions should be confirmed from the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 10 Tablets\nGLIEMPAFLOZIN 3D 10 combines three established antidiabetic medicines with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: Targets different processes involved in blood glucose regulation.\nExtended-release metformin: Provides a formulation designed to release Metformin gradually over time.\nOral tablet dosage form: Allows administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThe combination is not suitable for every person with diabetes. Treatment decisions should be based on individual medical needs and the approved product information.\n\nUses of GLIEMPAFLOZIN 3D 10\nGLIEMPAFLOZIN 3D 10 is intended for the management of type 2 diabetes mellitus, subject to its approved indications and the prescribing healthcare professional's assessment.\n\nType 2 diabetes is a chronic metabolic condition characterized by impaired insulin action and, in many patients, insufficient insulin production. Persistently elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three active ingredients in GLIEMPAFLOZIN 3D 10 address different aspects of glucose regulation. A healthcare professional may consider this combination when multiple medicines are required to achieve an individual's treatment goals and when the combination is clinically appropriate.\n\nThe medicine should be used as part of a comprehensive diabetes-management plan that may include balanced nutrition, regular physical activity, blood glucose monitoring, and routine medical assessments. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 10 Work?\n1. Empagliflozin 10 mg\nEmpagliflozin belongs to the SGLT2 inhibitor class. It blocks a protein responsible for reabsorbing glucose filtered by the kidneys. This allows more glucose to be eliminated through urine, helping reduce blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. Whether these benefits apply to an individual depends on their clinical condition and the applicable prescribing information.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. By increasing incretin activity, Sitagliptin supports insulin release when blood glucose is elevated and helps regulate glucagon secretion. These actions contribute to blood glucose control.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily reduces glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nTogether, these ingredients target several pathways involved in type 2 diabetes. Their combined effectiveness and safety depend on appropriate prescribing, correct administration, and regular monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 10\nWhen prescribed for an appropriate patient, GLIEMPAFLOZIN 3D 10 may offer the following treatment advantages:\n\nMultiple mechanisms of action: Combines three medicines that influence different aspects of glucose regulation.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nCombination therapy: May simplify a treatment regimen compared with taking the same ingredients as separate tablets.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nPersonalized treatment options: May be considered when a healthcare professional determines that triple therapy is appropriate.\nIndividual outcomes vary, and the medicine does not replace a suitable diet, physical activity, or routine diabetes care.\n\nDirections for Use\nTake GLIEMPAFLOZIN 3D 10 only as prescribed by your healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or your prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or stop treatment without consulting your prescriber.\nAttend recommended appointments for kidney-function assessment and blood glucose monitoring.\nIf you miss a dose, follow the official patient information or ask your healthcare professional or pharmacist what to do. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 10 is a prescription medicine and may not be suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important kidney-related prescribing considerations.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients at risk of dehydration or low blood pressure should discuss appropriate precautions with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin may increase the risk of genital fungal infections and can be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, or excessive alcohol intake.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nHypoglycemia: Low blood glucose may occur, particularly when the combination is used with insulin or insulin secretagogues such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, and upcoming procedures involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 10?\nGLIEMPAFLOZIN 3D 10 brings together Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg in a triple-combination tablet intended for selected patients with type 2 diabetes.\n\nFor pharmaceutical websites, pharmacies, distributors, and healthcare professionals, clear information about composition, mechanism of action, potential uses, and precautions supports responsible product awareness.\n\nAlways refer to the approved product label for the exact composition, indications, dosage, contraindications, storage requirements, and instructions for use.\n\nConclusion\nGLIEMPAFLOZIN 3D 10 Tablets combine Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. The combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 10?\n\nGLIEMPAFLOZIN 3D 10 is a combination tablet containing Empagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 10 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom this combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 10 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 10 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 10 suitable for everyone with diabetes?\n\nNo. Suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and approved prescribing information.\n\n", "price": 210.0, "discountamount": 147.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2505, "imageuri": "https://productimages.withfloats.com/actual/6ad7470422551901df6e5493.png", "tileimageuri": "https://productimages.withfloats.com/tile/6ad7470422551901df6e5493.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-10-20T10:48:34.116Z", "updatedon": "2026-10-20T10:48:34.116Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliozin-10-mg-sitagliptin-100-mg-and-metformin-hydrochloride-1000-mg-er-tablets/2505", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN 3D 10", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6ad7442bf24c5a4bbccf4b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin,Sitagliptin And Metformin Hydrochloride (ER) Tablets", "description": "GLIEMPAFLOZIN 3D 25 is a combination pharmaceutical product containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride Extended Release (ER) 1000 mg. This triple-combination formulation is intended for the management of type 2 diabetes mellitus in appropriate patients, as determined by a qualified healthcare professional.\n\nThe three active ingredients work through different mechanisms to help control blood glucose levels. Empagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin is a biguanide antidiabetic medicine. Together, these ingredients target different pathways involved in glucose regulation.\n\nGLIEMPAFLOZIN 3D 25 provides a combination of three established antidiabetic agents in a single tablet. Its suitability depends on the patient's blood glucose levels, kidney function, current diabetes treatment, medical history, and the approved prescribing information.\n\nComposition of GLIEMPAFLOZIN 3D 25\nEach tablet contains the following stated active ingredients:\n\nEmpagliflozin 25 mg: An SGLT2 inhibitor that helps the kidneys remove glucose from the bloodstream through urine.\nSitagliptin 100 mg: A DPP-4 inhibitor that increases the activity of incretin hormones involved in glucose-dependent insulin release and glucagon regulation.\nMetformin Hydrochloride ER 1000 mg: An extended-release biguanide that primarily reduces glucose production in the liver and improves the body's response to insulin.\nThe exact formulation, excipients, administration instructions, and approved indications should be verified against the product packaging and official prescribing information.\n\nKey Features of GLIEMPAFLOZIN 3D 25\nGLIEMPAFLOZIN 3D 25 combines three antidiabetic ingredients with complementary mechanisms of action.\n\nTriple-combination formulation: Contains Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER.\nMultiple glucose-control pathways: The ingredients act through different mechanisms involved in blood glucose regulation.\nExtended-release metformin: The ER formulation is designed to release metformin over an extended period.\nOral tablet dosage form: Provides oral administration according to the prescribed regimen.\nIndividualized diabetes management: May be considered by a healthcare professional when combination therapy is appropriate.\nThe benefits of this combination depend on the patient's clinical needs and the suitability of all three ingredients.\n\nUses of GLIEMPAFLOZIN 3D 25 Tablets\nGLIEMPAFLOZIN 3D 25 is intended for the management of type 2 diabetes mellitus, subject to the product's approved indications and the prescribing healthcare professional's judgment.\n\nType 2 diabetes is a chronic metabolic condition in which the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood glucose levels. Long-term elevated blood glucose can increase the risk of complications affecting the eyes, kidneys, nerves, heart, and blood vessels.\n\nThe three medicines in GLIEMPAFLOZIN 3D 25 target different aspects of glucose regulation. A healthcare professional may consider a combination regimen when an individual's treatment goals are not adequately achieved with a simpler regimen or when the combination is otherwise clinically appropriate.\n\nThe medicine should be used alongside an individualized diabetes-management plan that may include a balanced diet, physical activity, glucose monitoring, and regular medical follow-up. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.\n\nHow Does GLIEMPAFLOZIN 3D 25 Work?\nThe three active ingredients contribute to blood glucose management through distinct mechanisms.\n\n1. Empagliflozin 25 mg\nEmpagliflozin inhibits SGLT2, a protein responsible for reabsorbing much of the glucose filtered by the kidneys. By reducing glucose reabsorption, it increases glucose excretion through urine and helps lower blood glucose levels.\n\nEmpagliflozin has also demonstrated cardiovascular and kidney benefits in certain eligible patient populations. These benefits depend on the patient's condition and the applicable prescribing information and should not be assumed to apply identically to every patient.\n\n2. Sitagliptin 100 mg\nSitagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. Increasing incretin activity helps stimulate insulin release when blood glucose is elevated and reduces glucagon secretion when appropriate. This helps regulate glucose levels, particularly after meals.\n\n3. Metformin Hydrochloride ER 1000 mg\nMetformin primarily decreases glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine gradually over time.\n\nBy combining these mechanisms, GLIEMPAFLOZIN 3D 25 targets several pathways involved in type 2 diabetes. Its overall effectiveness and safety depend on appropriate patient selection, dosing, and ongoing monitoring.\n\nPotential Benefits of GLIEMPAFLOZIN 3D 25\nWhen prescribed for an appropriate patient, this combination may offer the following treatment advantages:\n\nMultiple mechanisms of action: Addresses glucose regulation through three different pharmacological pathways.\nBlood glucose management: Helps improve glycemic control in eligible adults with type 2 diabetes.\nOral combination therapy: Combines three medicines in one tablet, which may simplify a prescribed regimen compared with taking each ingredient separately.\nExtended-release component: Includes Metformin Hydrochloride ER for gradual drug release.\nIndividualized treatment options: May be considered when a healthcare professional determines that all three ingredients are appropriate.\nThese potential advantages do not guarantee a particular result. Treatment effectiveness depends on adherence, diet, physical activity, individual health status, and medical supervision.\n\nDirections for Use\nGLIEMPAFLOZIN 3D 25 should be taken only as prescribed by a qualified healthcare professional.\n\nFollow the prescribed dose and administration schedule.\nTake the tablet with food if directed by the product labeling or prescriber.\nSwallow the extended-release tablet whole unless the specific product instructions state otherwise. Do not crush, chew, or split it without professional guidance.\nDo not change the dose or discontinue treatment without consulting your prescriber.\nAttend recommended appointments for blood glucose monitoring and kidney-function assessment.\nIf a dose is missed, follow the official patient information or ask your healthcare professional or pharmacist for advice. Do not take an extra dose to compensate for a missed dose unless specifically instructed.\n\nPrecautions and Safety Information\nGLIEMPAFLOZIN 3D 25 is a prescription medicine and is not suitable for everyone.\n\nKidney function: Kidney function should be assessed before and during treatment as appropriate. Metformin and Empagliflozin have important renal considerations, and the combination may be unsuitable at certain levels of kidney impairment.\n\nDehydration: Empagliflozin increases glucose excretion through urine and may increase urination. Patients should discuss dehydration risk, low blood pressure, and fluid intake with their healthcare professional.\n\nGenital and urinary infections: Empagliflozin can increase the risk of genital fungal infections and may be associated with urinary tract infections.\n\nLactic acidosis: Metformin can rarely cause a serious condition called lactic acidosis. Risk may increase with significant kidney impairment, severe dehydration, certain acute illnesses, excessive alcohol intake, or other predisposing conditions.\n\nPancreatitis: Pancreatitis has been reported in patients taking Sitagliptin. Severe, persistent abdominal pain requires prompt medical assessment.\n\nLow blood glucose: The risk of hypoglycemia may increase when this combination is used with insulin or insulin secretagogues, such as sulfonylureas.\n\nInform your healthcare professional about existing medical conditions, all medicines you take, pregnancy or breastfeeding, planned surgery, prolonged fasting, or an upcoming medical procedure involving iodinated contrast. Follow professional instructions about temporary medicine interruption during acute illness or other high-risk situations.\n\nSeek urgent medical care for severe abdominal pain, difficulty breathing, unusual weakness, persistent vomiting, severe dehydration, or other serious symptoms.\n\nWhy Choose GLIEMPAFLOZIN 3D 25?\nGLIEMPAFLOZIN 3D 25 brings together Empagliflozin, Sitagliptin, and Metformin Hydrochloride ER in a triple-combination tablet designed for the management of type 2 diabetes in appropriately selected patients.\n\nFor pharmaceutical product catalogues, distributors, pharmacies, and healthcare professionals, accurate information about the composition, mechanism of action, approved indications, and safety profile supports responsible product awareness.\n\nTreatment decisions should always be based on the patient's medical assessment and the approved product information.\n\nConclusion\nGLIEMPAFLOZIN 3D 25 Tablets combine Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg to target multiple pathways involved in blood glucose regulation. This combination may be appropriate for selected adults with type 2 diabetes under medical supervision.\n\nFor complete information about dosage, contraindications, warnings, storage, and approved indications, consult the official product packaging and prescribing information. Use this medicine only under the direction of a qualified healthcare professional.\n\nFrequently Asked Questions (FAQs)\n1. What is GLIEMPAFLOZIN 3D 25?\n\nGLIEMPAFLOZIN 3D 25 is a combination tablet containing Empagliflozin 25 mg, Sitagliptin 100 mg, and Metformin Hydrochloride ER 1000 mg.\n\n2. What is GLIEMPAFLOZIN 3D 25 used for?\n\nIt is intended for the management of type 2 diabetes mellitus in patients for whom the combination is considered appropriate by a healthcare professional.\n\n3. How does GLIEMPAFLOZIN 3D 25 work?\n\nEmpagliflozin increases urinary glucose excretion, Sitagliptin supports glucose-dependent insulin regulation, and Metformin reduces glucose production in the liver and improves insulin sensitivity.\n\n4. Can GLIEMPAFLOZIN 3D 25 replace diet and exercise?\n\nNo. Medication should be combined with an individualized diet, physical activity, and monitoring plan as recommended by a healthcare professional.\n\n5. Is GLIEMPAFLOZIN 3D 25 suitable for everyone with diabetes?\n\nNo. Its suitability depends on the type of diabetes, kidney function, other medical conditions, concurrent medicines, and the approved prescribing information.", "price": 230.0, "discountamount": 69.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2504, "imageuri": "https://productimages.withfloats.com/actual/6ad7442d6e565c5fe6e5b7cb.png", "tileimageuri": "https://productimages.withfloats.com/tile/6ad7442d6e565c5fe6e5b7cb.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-10-20T10:36:27.325Z", "updatedon": "2026-10-20T10:36:27.325Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//empagliflozin-sitagliptin-and-metformin-hydrochloride-er-tablets/2504", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN 3D 25", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a8c3838c90065ecdc86c757", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide Injection 4mg", "description": "SAMIGLUTIDE 4 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation contains 4 mg of semaglutide in 3 mL of solution, corresponding to approximately 1.34 mg/mL.\n\nSemaglutide is a GLP-1 receptor agonist that acts on physiological pathways involved in blood-glucose control, appetite, and gastrointestinal function. Its use should be based on the approved indication for the specific product and the advice of a qualified healthcare professional.\n\nProduct Overview\nProduct: SAMIGLUTIDE 4 MG\nActive substance: Semaglutide\nStrength: 4 mg/3 mL\nApproximate concentration: 1.34 mg/mL\nDosage form: Injectable solution\nPresentation: Pre-filled pen\nRoute: Subcutaneous administration, according to the applicable product instructions\n\nThe 4 mg/3 mL concentration is also associated with certain approved semaglutide products. However, this does not mean that their dosing schedules, indications, or administration instructions automatically apply to SAMIGLUTIDE 4 MG. The product-specific labeling should always be followed.\n\nWhat Is Semaglutide?\n\nSemaglutide is a medication belonging to the GLP-1 receptor agonist class. It acts similarly to the naturally occurring hormone glucagon-like peptide-1 (GLP-1).\n\nGLP-1 is involved in several processes related to metabolism. Its activity can influence insulin secretion, glucagon regulation, stomach emptying, and appetite. Depending on the particular semaglutide product and its regulatory authorization, semaglutide may be prescribed for conditions such as type 2 diabetes or chronic weight management in appropriately selected patients.\n\nBecause different semaglutide products can have different approved uses and formulations, treatment decisions should be based on the specific medicine being prescribed.\n\nSAMIGLUTIDE 4 MG Pre-Filled Pen\n\nSAMIGLUTIDE 4 MG is supplied in a pre-filled pen intended to provide a convenient format for subcutaneous administration.\n\nPre-filled devices can eliminate the need to draw medication from a conventional vial. Nevertheless, patients should be properly trained before using an injectable pen and should follow the instructions supplied with the specific product.\n\nThe pen should only be used according to its approved instructions, including the prescribed dose and administration schedule.\n\nStrength and Formulation\n\nEach stated 3 mL presentation contains 4 mg of semaglutide, giving a concentration of approximately 1.34 mg/mL.\n\nThe concentration of a medicine should not be confused with the amount delivered in every injection. The quantity administered depends on the design and dose settings of the particular pen.\n\nFor this reason, patients should not calculate or select their own dose based solely on the concentration printed on the package. The prescribed dose should come from the product's authorized instructions and the treating healthcare professional.\n\nHow Semaglutide Acts\n\nSemaglutide activates GLP-1 receptors, which are involved in the regulation of blood glucose and appetite.\n\nAmong its physiological effects, GLP-1 receptor activation can:\n\nSupport glucose-dependent insulin secretion.\nReduce inappropriate glucagon secretion when blood glucose is elevated.\nAffect gastrointestinal activity, including gastric emptying.\nInfluence appetite and food intake.\n\nThe overall response to treatment can vary between individuals and depends on factors such as the medical indication, prescribed dose, treatment duration, and other medicines being used.\n\nPotential Therapeutic Benefits\n\nWhen prescribed for an appropriate, authorized indication, semaglutide may form part of a broader treatment program.\n\nFor eligible individuals with type 2 diabetes, certain approved semaglutide medicines are used to improve glycemic control. Other approved semaglutide formulations have indications involving chronic weight management for qualifying patients.\n\nMedication should be considered alongside the broader treatment strategy recommended by a healthcare professional, which may include nutritional management, physical activity, glucose monitoring, and other appropriate interventions.\n\nPossible Side Effects\n\nLike other prescription medicines, semaglutide can cause unwanted effects.\n\nFrequently reported gastrointestinal reactions associated with semaglutide products include:\n\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort or pain\n\nNot every patient experiences these effects, and their severity can vary.\n\nSemaglutide products also have important safety considerations. Depending on the specific approved product, labeling includes warnings concerning conditions such as pancreatitis, gallbladder-related problems, severe gastrointestinal reactions, kidney problems associated with dehydration, and serious hypersensitivity reactions.\n\nPatients should provide their healthcare professional with a complete medical history before treatment begins.\n\nImportant Contraindications and Warnings\n\nCertain semaglutide products carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity to semaglutide or an applicable component is also an important contraindication.\n\nThe exact warnings and contraindications applicable to SAMIGLUTIDE 4 MG should be confirmed against its current authorized product information in the relevant country.\n\nPatients should seek professional medical advice if they develop concerning symptoms during treatment.\n\nCorrect Administration\n\nSAMIGLUTIDE 4 MG should be administered only according to the prescription and instructions applicable to the product.\n\nBefore using a pre-filled pen, patients should receive appropriate instruction regarding:\n\nDose selection\nInjection technique\nInjection sites\nPen operation\nStorage\nDisposal of used needles or injection equipment\n\nThe dose or frequency should never be changed independently.\n\nA pre-filled injection pen should not be shared with another person, even if a new needle is attached. Sharing injectable medication devices can create a risk of transmitting infections and is contrary to appropriate safe-use practices.\n\nStorage\n\nStorage requirements should be determined from the official SAMIGLUTIDE 4 MG packaging and product information supplied with the medicine.\n\nPatients should not rely on storage instructions from a different semaglutide brand because formulations, devices, and stability requirements can differ between products.\n\nUse by Healthcare Professionals\n\nHealthcare professionals should assess whether SAMIGLUTIDE 4 MG is appropriate for an individual patient by considering the relevant diagnosis, treatment objectives, medical history, contraindications, concurrent medicines, and applicable regulatory requirements.\n\nParticular attention should be given to the distinction between different semaglutide products. Although they contain the same active ingredient, products may differ in:\n\nApproved indications\nConcentration\nPen design\nDose increments\nAdministration schedules\nStorage conditions\nRegulatory labeling\n\nThe product-specific prescribing information should therefore be consulted before treatment is initiated or adjusted.\n\nAdvantages of a Pre-Filled Pen\n\nA pre-filled pen can provide a practical method of administering an injectable medicine. Compared with a conventional vial-and-syringe presentation, the device may reduce some preparation steps and can be convenient for patients who have been appropriately trained.\n\nConvenience, however, should not take precedence over product authenticity, regulatory approval, correct dosing, proper storage, and professional medical supervision.\n\nSAMIGLUTIDE 4 MG: Key Points\n\nSAMIGLUTIDE 4 MG is described as a semaglutide injection containing 4 mg in 3 mL, supplied in a pre-filled pen.\n\nThe most important considerations are:\n\nSemaglutide is a GLP-1 receptor agonist.\nThe stated formulation is 4 mg/3 mL (approximately 1.34 mg/mL).\nAdministration is by the subcutaneous route when prescribed for that route.\nThe appropriate dose and frequency must come from the product-specific instructions and prescription.\nDosing information from another semaglutide brand should not automatically be applied.\nPatients should be informed about possible adverse reactions and relevant contraindications.\nThe pen must not be shared between patients.\nStorage and handling should follow the official product information.\nTreatment should be supervised by an appropriately qualified healthcare professional.\nFrequently Asked Questions\nWhat is SAMIGLUTIDE 4 MG?\n\nSAMIGLUTIDE 4 MG is a semaglutide-containing injectable formulation described as 4 mg/3 mL, supplied in a pre-filled pen. Its approved use depends on the regulatory authorization applicable to the product and market.\n\nWhat does 4 mg/3 mL mean?\n\nIt indicates that the stated 3 mL presentation contains a total of 4 mg of semaglutide, equivalent to approximately 1.34 mg of semaglutide per mL.\n\nThis concentration alone should not be used to determine an individual's injection dose.\n\nIs SAMIGLUTIDE 4 MG a prescription medicine?\n\nSemaglutide medicines are prescription products in many jurisdictions. SAMIGLUTIDE 4 MG should be used only in accordance with applicable regulations, authorized product information, and professional medical advice.\n\nHow is SAMIGLUTIDE 4 MG administered?\n\nThe product is described as a subcutaneous injection. However, the exact dose, injection frequency, and pen operation should be determined from the SAMIGLUTIDE 4 MG product information and the patient's prescription.\n\nCan SAMIGLUTIDE 4 MG be taken together with another semaglutide medicine?\n\nPatients should not combine semaglutide-containing medicines or switch between them without medical supervision. Some approved semaglutide labels specifically advise against combining their product with another semaglutide-containing medicine or another GLP-1 receptor agonist.\n\nCan the dose be changed without consulting a doctor?\n\nNo. Patients should not increase, decrease, or otherwise modify the prescribed dose or injection schedule without guidance from their healthcare professional.\n\nConclusion\n\nSAMIGLUTIDE 4 MG – Semaglutide Injection 4 mg/3 mL (approximately 1.34 mg/mL) Pre-Filled Pen is a semaglutide-based injectable formulation designed for subcutaneous use according to its applicable product instructions.\n\nBecause semaglutide products can vary substantially in their approved indications, concentrations, devices, and dosing regimens, information from another semaglutide product should not be assumed to apply to SAMIGLUTIDE 4 MG.\n\nFor appropriate and safe use, patients and healthcare professionals should rely on the current official product information, local regulatory authorization, and individualized medical advice. Any questions concerning suitability, dosing, interactions, contraindications, or adverse effects should be discussed with a qualified healthcare professional.", "price": 6600.0, "discountamount": 1980.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2497, "imageuri": "https://productimages.withfloats.com/actual/6a8c383c0e00e8a5dab0c9d5.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a8c383c0e00e8a5dab0c9d5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-24T12:25:28.659Z", "updatedon": "2026-08-24T12:25:28.659Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//semaglutide-injection-4mg/2497", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 4 MG", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6a8c35e76d1f6b0cbc0e2e40", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Semaglutide Injection 2 mg", "description": "SAMIGLUTIDE 2 MG is a semaglutide-containing injectable medicine supplied in a pre-filled pen. The stated formulation is Semaglutide Injection 2 mg/3 mL (0.68 mg/mL). Semaglutide belongs to the GLP-1 receptor agonist class and is a prescription medicine that should be used only under the supervision of an appropriately qualified healthcare professional.\n\nSAMIGLUTIDE 2 MG Composition\n\nEach 3 mL pre-filled pen is stated to contain:\n\nActive substance: Semaglutide\nStrength: 2 mg/3 mL\nConcentration: 0.68 mg/mL\nDosage form: Injectable solution\nPresentation: Pre-filled pen\nRoute of administration: Subcutaneous, according to the applicable product instructions\n\nSemaglutide acts on GLP-1 receptors, which are involved in blood-glucose regulation and appetite control. The approved uses, dosage regimen and strength available can differ according to the specific product and the regulations of the country in which it is supplied.\n\nWhat Is Semaglutide?\n\nSemaglutide is a synthetic peptide that mimics the activity of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). By activating GLP-1 receptors, it can influence several physiological processes, including glucose-dependent insulin release, glucagon secretion, gastric emptying and appetite.\n\nThe appropriate dose and treatment schedule depend on the individual patient and the particular semaglutide formulation. Patients should follow their healthcare professional's instructions and should not alter the prescribed regimen independently.\n\nSAMIGLUTIDE 2 MG Pre-Filled Pen\n\nSAMIGLUTIDE 2 MG is presented as a pre-filled injection pen intended to provide a convenient method of administration when the medicine has been prescribed.\n\nSince semaglutide products can differ in concentration, pen design and dose-delivery mechanism, users should carefully verify the product label and prescribed dose before each administration. Particular care is important with injectable semaglutide products because differences in concentration or measurement methods can result in medication errors.\n\nPotential Medical Uses\n\nSemaglutide may be used for particular medical conditions depending on the formulation, regulatory approval and prescribing information applicable to the product.\n\nCertain approved semaglutide medicines are indicated for the treatment of type 2 diabetes, while other formulations have approved indications involving chronic weight management in eligible patients. Some products may also have additional approved indications for reducing specific cardiovascular risks.\n\nThe fact that semaglutide can be used for weight management does not mean that every semaglutide product is approved for that purpose. The authorization and labeling of SAMIGLUTIDE should therefore be confirmed from current official product documentation.\n\nHow Semaglutide Works\n\nSemaglutide activates GLP-1 receptors in the body. Its effects can contribute to improved regulation of blood glucose and reduced appetite and food intake. Depending on the approved indication, it may be prescribed together with dietary, physical-activity or other appropriate medical measures.\n\nIndividual responses can vary. Medical follow-up helps healthcare professionals evaluate treatment response, tolerability and whether treatment should be continued or modified.\n\nDosage and Administration\n\nSAMIGLUTIDE 2 MG should be administered only in accordance with the prescription and the manufacturer's current instructions.\n\nThe amount of semaglutide contained in a pen should not automatically be interpreted as the amount to inject at one time. Different products may use different concentrations, dose settings and administration schedules.\n\nFor approved semaglutide products, treatment may involve gradual dose increases for certain indications. Patients should never increase the dose, inject more frequently or repeat a missed dose without receiving appropriate medical instructions.\n\nPossible Side Effects\n\nSemaglutide can cause adverse effects, particularly gastrointestinal symptoms. Frequently reported effects may include:\n\nNausea\nVomiting\nDiarrhea\nConstipation\nAbdominal discomfort\nAbdominal pain\n\nMore serious reactions are also possible. Product information for semaglutide medicines includes warnings relating to conditions such as pancreatitis and gallbladder disorders, among other potential risks.\n\nPersistent, severe or unusual symptoms should be discussed promptly with a healthcare professional. Patients should review the complete prescribing information supplied with their particular product.\n\nImportant Safety Information\n\nSemaglutide is not appropriate for everyone. For example, certain approved semaglutide products in the United States carry a contraindication for individuals with a personal or family history of medullary thyroid carcinoma (MTC), people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and individuals with a serious hypersensitivity to semaglutide or an ingredient in the relevant product.\n\nThese precautions should not automatically be assumed to apply identically to every semaglutide product worldwide. The manufacturer's labeling and the regulatory requirements of the relevant country should always be consulted.\n\nPatients should inform their healthcare professional about their medical history and other medicines before starting treatment.\n\nAdvantages of a Pre-Filled Pen\n\nA pre-filled pen can make injectable treatment more convenient by providing the medication in a ready-to-use delivery device. When used according to the manufacturer's instructions, the pen may simplify administration and help patients maintain their prescribed treatment routine.\n\nPatients should nevertheless receive appropriate guidance regarding injection technique, storage, handling and disposal. The convenience of a pen does not eliminate the need for medical supervision.\n\nStorage and Handling\n\nSAMIGLUTIDE 2 MG should be stored exactly as stated on its packaging and official product information. Appropriate storage conditions are important for maintaining the quality and stability of the medicine.\n\nBefore use, check the expiry date and inspect the packaging and medicine according to the manufacturer's instructions. Do not use the product if the packaging is damaged or if the solution has an appearance that does not meet the stated product requirements.\n\nConclusion\n\nSAMIGLUTIDE 2 MG – Semaglutide Injection 2 mg/3 mL (0.68 mg/mL) is a semaglutide-based injectable formulation supplied in a pre-filled pen. Semaglutide is a GLP-1 receptor agonist with established medical applications for appropriately selected patients, depending on the specific product and its regulatory authorization.\n\nSafe use requires adherence to the prescribed dose and administration schedule. Patients should not independently change their dose or frequency and should seek professional advice if they experience concerning adverse effects.\n\nBecause formulations, indications, strengths and regulatory requirements can vary between products and countries, the current official package insert and applicable regulatory labeling should be used to verify product-specific information.\n\nFrequently Asked Questions\nWhat is SAMIGLUTIDE 2 MG?\n\nSAMIGLUTIDE 2 MG is described as a semaglutide injection containing 2 mg of semaglutide in 3 mL, with a stated concentration of 0.68 mg/mL, supplied in a pre-filled pen.\n\nIs SAMIGLUTIDE 2 MG used for weight management?\n\nSemaglutide is included in certain approved medicines used for chronic weight management in eligible patients. However, the indication for a specific SAMIGLUTIDE product must be confirmed from its current regulatory approval and official labeling.\n\nHow frequently is SAMIGLUTIDE 2 MG injected?\n\nThe correct frequency depends on the specific product and the prescription issued by the healthcare professional. Patients should not determine the injection schedule based solely on the amount printed on the pen.\n\nCan SAMIGLUTIDE 2 MG be taken without medical supervision?\n\nNo. Semaglutide is a prescription medicine in many jurisdictions and should be obtained and used through legitimate, appropriately regulated healthcare channels.\n\nIs SAMIGLUTIDE the same as other branded semaglutide medicines?\n\nNot necessarily. Products containing semaglutide can differ in manufacturer, formulation, concentration, delivery device, regulatory approval and approved indications. A specific product should not be described as identical to an approved branded medicine unless that claim can be verified through reliable regulatory and product documentation.\n\nWhat should patients check before using the pen?\n\nPatients should verify the medicine name, strength, prescribed dose, expiry date, storage conditions and administration instructions. If there is any uncertainty about the dose or operation of the pen, they should consult their pharmacist, prescriber or another qualified healthcare professional rather than guessing.", "price": 5600.0, "discountamount": 1680.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2496, "imageuri": "https://productimages.withfloats.com/actual/6a8c35eaca4d2575d78e3716.png", "tileimageuri": "https://productimages.withfloats.com/tile/6a8c35eaca4d2575d78e3716.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-08-24T12:15:35.873Z", "updatedon": "2026-08-24T12:15:35.873Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//semaglutide-injection-2-mg/2496", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "SAMIGLUTIDE 2 MG", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }